Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › BMRN
RICE HALL JAMES & ASSOCIATES, LLC position in BMRN
BIOMARIN PHARMACEUTICAL INC · Health Care
RICE HALL JAMES & ASSOCIATES, LLC reported holding 376,343 shares of BMRN (BIOMARIN PHARMACEUTICAL INC) in its Q3 2026 13F filing — a position valued at US$22.6M, representing 1.20% of its reported portfolio and ranking #29 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RICE HALL JAMES & ASSOCIATES, LLC's BMRN position evolved
RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in BMRN in Q3 2023 at 30,867 shares (US$2.7M). The position peaked in Q3 2026 at 376,343 shares, worth US$22.6M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 376,343 shares valued at US$22.6M — an increase of 128,119 shares quarter over quarter.. Notable position changes include a 1693% increase in Q3 2025 (shares rose 10% over the following quarter), a 137% increase in Q2 2026 (shares rose 5% over the following quarter), a 52% increase in Q3 2026 (shares fell 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 30.87K | $2.73M | New |
| Q4 2023 | 29.41K | $2.84M | Reduce |
| Q1 2024 | 28.72K | $2.51M | Reduce |
| Q2 2024 | 20.68K | $1.70M | Reduce |
| Q3 2024 | 10.33K | $725.88K | Reduce |
| Q4 2024 | 5.79K | $380.64K | Reduce |
| Q1 2025 | 5.88K | $415.66K | Add |
| Q2 2025 | 5.77K | $317.07K | Reduce |
| Q3 2025 | 103.42K | $5.60M | Add |
| Q4 2025 | 100.17K | $5.95M | Reduce |
| Q1 2026 | 104.66K | $5.91M | Add |
| Q2 2026 | 248.22K | $14.20M | Add |
| Q3 2026 | 376.34K | $22.58M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC) is a Health Care company. 26 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$899.3M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.99M sh · $899.34M · Q3 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Deep Track Capital, LP 6.37M sh · $382.46M · Q3 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $108.89M · Q2 2026
More on RICE HALL JAMES & ASSOCIATES, LLC
FAQ
How long has RICE HALL JAMES & ASSOCIATES, LLC held BMRN?
RICE HALL JAMES & ASSOCIATES, LLC has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RICE HALL JAMES & ASSOCIATES, LLC's current position in BMRN?
As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 376.34K shares of BMRN (BIOMARIN PHARMACEUTICAL INC), valued at $22.58M, representing 1.20% of its reported portfolio and ranking #29.
Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling BMRN?
In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC increased its position in BMRN. The position peaked in Q3 2026 at 376.34K shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.